These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 12958789)

  • 1. [Recurrence prophylaxis for stroke patients. Which platelet inhibitor combination protects best?].
    MMW Fortschr Med; 2003 Jul; 145(29-30):63. PubMed ID: 12958789
    [No Abstract]   [Full Text] [Related]  

  • 2. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS).
    Diener HC; Sacco R; Yusuf S; ;
    Cerebrovasc Dis; 2007; 23(5-6):368-80. PubMed ID: 17337887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correction to the PRoFESS Trial paper by Diener et al. (Cerebrovasc Dis 2007;23:368-80.
    Sacco R; Diener HC; Yusuf S
    Cerebrovasc Dis; 2008; 25(1-2):192. PubMed ID: 18416019
    [No Abstract]   [Full Text] [Related]  

  • 4. [PRoFESS study presented. Change in secondary prevention].
    MMW Fortschr Med; 2003 May; 145 Suppl 2():96-7. PubMed ID: 14579494
    [No Abstract]   [Full Text] [Related]  

  • 5. Secondary stroke prevention set to benefit from PRoFESS trial: extended-release dipyridamole plus aspirin (Asasantin Retard) and clopidogrel share very similar benefit-risk ratio in vascular prevention.
    Cardiovasc J Afr; 2008; 19(3):165. PubMed ID: 18568182
    [No Abstract]   [Full Text] [Related]  

  • 6. PRoFESS.
    Lees KR
    Stroke; 2009 May; 40(5):1941. PubMed ID: 19038905
    [No Abstract]   [Full Text] [Related]  

  • 7. [ASS plus dipyridamole or clopidogrel after stroke: what is the best secondary prevention?].
    Einecke D
    MMW Fortschr Med; 2008 May; 150(21):6-7. PubMed ID: 18575244
    [No Abstract]   [Full Text] [Related]  

  • 8. Secondary prevention in the acute and early chronic phase after ischaemic stroke and transient ischaemic attacks with antiplatelet drugs--is antiplatelet monotherapy still reasonable?
    Diener HC; Weber R; Weimar C; Röther J
    Int J Clin Pract; 2011 May; 65(5):531-5. PubMed ID: 21489077
    [No Abstract]   [Full Text] [Related]  

  • 9. Stroke prevention--insights from incoherence.
    Kent DM; Thaler DE
    N Engl J Med; 2008 Sep; 359(12):1287-9. PubMed ID: 18753641
    [No Abstract]   [Full Text] [Related]  

  • 10. [Platelet-function inhibitors in the secondary prevention of ischemic stroke].
    Busse O; Diener HC; Grond M
    Dtsch Med Wochenschr; 2006 Nov; 131 Suppl 5():S132-4. PubMed ID: 17089258
    [No Abstract]   [Full Text] [Related]  

  • 11. [Secondary stroke prevention according to the PRoFESS Study. What are the sequelae for practical therapy?].
    Diener C
    MMW Fortschr Med; 2008 May; 150(21):7. PubMed ID: 18578065
    [No Abstract]   [Full Text] [Related]  

  • 12. The approach to optimizing stroke care.
    Panagos PD
    Am J Emerg Med; 2008 Sep; 26(7):808-16. PubMed ID: 18774049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiplatelets for stroke prevention: implications of the PRoFESS trial.
    Selim M
    Stroke; 2009 May; 40(5):1936-7. PubMed ID: 19038907
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical trials and dipyridamole formulation selection.
    Derendorf H
    Cerebrovasc Dis; 2007; 23(1):72-3; author reply 73-4. PubMed ID: 17108677
    [No Abstract]   [Full Text] [Related]  

  • 15. Secondary stroke prevention with antiplatelet therapy with emphasis on the cardiac patient: a neurologist's view.
    Gebel JM
    J Am Coll Cardiol; 2005 Sep; 46(5):752-5. PubMed ID: 16139120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Counting the true cost of antiplatelet therapy for stroke prevention.
    Morton JA; Newton J; Gray CS
    Age Ageing; 2005 May; 34(3):212-4. PubMed ID: 15863405
    [No Abstract]   [Full Text] [Related]  

  • 17. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
    Serebruany VL; Malinin AI; Pokov AN; Hanley DF
    Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiplatelet therapy to prevent recurrent stroke: Three good options.
    Mansoor AH; Mujtaba MT; Silver B
    Cleve Clin J Med; 2013 Dec; 80(12):787-95. PubMed ID: 24307163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Newer antiplatelet therapies in stroke prevention.
    Davis SM; Donnan GA
    Aust Fam Physician; 2001 Feb; 30(2):129-34. PubMed ID: 11280112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study.
    Diener HC; Sacco RL; Yusuf S; Cotton D; Ounpuu S; Lawton WA; Palesch Y; Martin RH; Albers GW; Bath P; Bornstein N; Chan BP; Chen ST; Cunha L; Dahlöf B; De Keyser J; Donnan GA; Estol C; Gorelick P; Gu V; Hermansson K; Hilbrich L; Kaste M; Lu C; Machnig T; Pais P; Roberts R; Skvortsova V; Teal P; Toni D; VanderMaelen C; Voigt T; Weber M; Yoon BW;
    Lancet Neurol; 2008 Oct; 7(10):875-84. PubMed ID: 18757238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.